Tivantinib added to erlotinib in nonsmall-cell lung cancer: the primary end point was not MET....


The transmembrane tyrosine kinase receptor mesenchymal– epithelial transition (MET) factor, activated by its ligand hepatocyte growth factor (HGF), is involved in cell proliferation, survival, motility, and metastasis [1]. The MET pathway is known to crosstalk with the epidermal growth factor receptor (EGFR) and KRAS signaling pathways, which are critical… (More)
DOI: 10.1093/annonc/mdv334


1 Figure or Table

Slides referencing similar topics